華潤醫藥(03320.HK)旗下抗血小板凝集注射液獲藥品註冊證書

阿斯達克財經

2025/09/17

華潤醫藥(03320.HK) 宣佈，集團旗下安徽雙鶴藥業有限責任公司收到國家藥品監督管理局頒發的鹽酸替羅非班氯化鈉注射液《藥品註冊證書》。鹽酸替羅非班氯化鈉注射液是一種抗血小板凝集藥，主要用於末次胸痛發作12小時之內且伴有ECG改變和/或心肌酶升高的非ST段抬高型急性冠脈綜合徵(NSTE-ACS)成年患者，預防早期心肌梗死。用於計劃進行直接PCI的急性心肌梗死患者(STEMI)，以減少重大心血管...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568040451"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568040451\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568040451?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240827115743024_s.jpg","is_english":false,"pubTime":"2025-09-17 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568040451","market":"fut","top_or_hot":-1,"title":"華潤醫藥(03320.HK)旗下抗血小板凝集注射液獲藥品註冊證書","media":"阿斯達克財經","content":"<div>\n<p>華潤醫藥(03320.HK) 宣佈，集團旗下安徽雙鶴藥業有限責任公司收到國家藥品監督管理局頒發的鹽酸替羅非班氯化鈉注射液《藥品註冊證書》。鹽酸替羅非班氯化鈉注射液是一種抗血小板凝集藥，主要用於末次胸痛發作12小時之內且伴有ECG改變和/或心肌酶升高的非ST段抬高型急性冠脈綜合徵(NSTE-ACS)成年患者，預防早期心肌梗死。用於計劃進行直接PCI的急性心肌梗死患者(STEMI)，以減少重大心血管...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1470925/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>華潤醫藥(03320.HK)旗下抗血小板凝集注射液獲藥品註冊證書</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n華潤醫藥(03320.HK)旗下抗血小板凝集注射液獲藥品註冊證書\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-09-17 12:24</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>華潤醫藥(03320.HK) 宣佈，集團旗下安徽雙鶴藥業有限責任公司收到國家藥品監督管理局頒發的鹽酸替羅非班氯化鈉注射液《藥品註冊證書》。鹽酸替羅非班氯化鈉注射液是一種抗血小板凝集藥，主要用於末次胸痛發作12小時之內且伴有ECG改變和/或心肌酶升高的非ST段抬高型急性冠脈綜合徵(NSTE-ACS)成年患者，預防早期心肌梗死。用於計劃進行直接PCI的急性心肌梗死患者(STEMI)，以減少重大心血管...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1470925/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1470925/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"華潤醫藥","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1470925/latest-news/AAFN","article_id":"2568040451","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240827115743024_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1470925/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2568040451","pubTimestamp":1758083040,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"華潤醫藥宣佈，集團旗下安徽雙鶴藥業有限責任公司收到國家藥品監督管理局頒發的鹽酸替羅非班氯化鈉注射液《藥品註冊證書》。集團表示，本次獲得鹽酸替羅非班氯化鈉注射液《藥品註冊證書》，將進一步豐富公司產品線，有助於提升公司產品的市場競爭力，對集團整體經營產生積極影響。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03320":"华润医药","BK1570":"华润系","BK1191":"制药"},"translate_title":"China Resources Pharmaceutical (03320. HK) 's antiplatelet agglutination injection obtained drug registration certificate","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1.5},"content_text":"華潤醫藥(03320.HK) 宣佈，集團旗下安徽雙鶴藥業有限責任公司收到國家藥品監督管理局頒發的鹽酸替羅非班氯化鈉注射液《藥品註冊證書》。鹽酸替羅非班氯化鈉注射液是一種抗血小板凝集藥，主要用於末次胸痛發作12小時之內且伴有ECG改變和/或心肌酶升高的非ST段抬高型急性冠脈綜合徵(NSTE-ACS)成年患者，預防早期心肌梗死。用於計劃進行直接PCI的急性心肌梗死患者(STEMI)，以減少重大心血管事件的發生。集團表示，本次獲得鹽酸替羅非班氯化鈉注射液《藥品註冊證書》，將進一步豐富公司產品線，有助於提升公司產品的市場競爭力，對集團整體經營產生積極影響。(hc/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-09-17 12:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}